What is a significant effect of maternal Zofran use during the first trimester?

Maternal use of Zofran (ondansetron) during the first trimester has been studied primarily with regard to its safety profile and potential risks to the developing fetus. The correct answer highlights the concern that this medication may be associated with an increased risk of congenital heart defects (CHD) in the fetus.

Research has indicated that while Zofran is commonly used to treat nausea and vomiting during pregnancy, particularly morning sickness, some studies have suggested a possible link between first-trimester Zofran exposure and an increased incidence of certain types of CHD. This finding has made healthcare providers more cautious when prescribing this medication during early pregnancy, emphasizing the importance of weighing the risks and benefits.

Other options do not accurately represent the established data surrounding Zofran use. For instance, while Zofran is effective in alleviating morning sickness, the potential risks, particularly concerning fetal heart development, have led to a careful reevaluation of its use during early pregnancy. There is no strong evidence that Zofran reduces the risk of preterm labor or that it contributes to autism spectrum disorder, which are common concerns but not supported by sufficient scientific evidence in this context.